Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Identification and function probing of an antithrombin IIIβ conformation-specific antibody.

Jin Y, Yegneswaran S, Gu JM, Gritzan U, Schönfeld DL, Paz P, Patel C, Dittmer F, Strerath M, Bringmann P, Kauser K, Myles T, Murphy JE, Hermiston TW.

J Thromb Haemost. 2016 Feb;14(2):356-65. doi: 10.1111/jth.13198. Epub 2016 Jan 6.

2.

Global substrate profiling of proteases in human neutrophil extracellular traps reveals consensus motif predominantly contributed by elastase.

O'Donoghue AJ, Jin Y, Knudsen GM, Perera NC, Jenne DE, Murphy JE, Craik CS, Hermiston TW.

PLoS One. 2013 Sep 20;8(9):e75141. doi: 10.1371/journal.pone.0075141. eCollection 2013.

3.

Oncolytic viruses: the power of directed evolution.

Bauzon M, Hermiston TW.

Adv Virol. 2012;2012:586389. doi: 10.1155/2012/586389. Epub 2011 Jul 24.

4.

Effect of different UCOE-promoter combinations in creation of engineered cell lines for the production of Factor VIII.

Nair AR, Jinger X, Hermiston TW.

BMC Res Notes. 2011 Jun 10;4:178. doi: 10.1186/1756-0500-4-178.

5.

Allogeneic somatic cell therapy: process development challenges and future opportunities.

Fawaz FS, Hermiston TW, Dinter H.

Curr Opin Mol Ther. 2010 Aug;12(4):383-5. Review.

PMID:
20707031
6.

Enhanced protein production using HBV X protein (HBx), and synergy when used in combination with XBP1s in BHK21 cells.

Jin F, Kretschmer PJ, Harkins RN, Hermiston TW.

Biotechnol Bioeng. 2010 Feb 1;105(2):341-9. doi: 10.1002/bit.22536.

PMID:
19739082
7.

Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV.

Ho DT, Wykoff-Clary S, Gross CS, Schneider D, Jin F, Kretschmer PJ, Hermiston TW.

Cancer Gene Ther. 2009 Feb;16(2):184-94. doi: 10.1038/cgt.2008.68. Epub 2008 Aug 29.

PMID:
18758433
8.

Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.

Bauzon M, Hermiston TW.

Curr Opin Mol Ther. 2008 Aug;10(4):350-5. Review.

PMID:
18683099
9.

Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.

Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, Seymour L, Rubanyi GM, Harkins RN, Hermiston TW.

PLoS One. 2008 Jun 18;3(6):e2409. doi: 10.1371/journal.pone.0002409.

10.

Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.

Petry H, Brooks A, Orme A, Wang P, Liu P, Xie J, Kretschmer P, Qian HS, Hermiston TW, Harkins RN.

Gene Ther. 2008 Jan;15(1):54-60. Epub 2007 Oct 25.

PMID:
17960164
11.

A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types.

Xie J, Nair A, Hermiston TW.

Toxicol In Vitro. 2008 Feb;22(1):261-6. Epub 2007 Sep 6.

PMID:
17928190
12.

Regulated expression of the interferon-beta gene in mice.

Harkins RN, Szymanski P, Petry H, Brooks A, Qian HS, Schaefer C, Kretschmer PJ, Orme A, Wang P, Rubanyi GM, Hermiston TW.

Gene Ther. 2008 Jan;15(1):1-11. Epub 2007 Jul 19.

PMID:
17637794
13.

Development and validation of a robust and versatile one-plasmid regulated gene expression system.

Szymanski P, Kretschmer PJ, Bauzon M, Jin F, Qian HS, Rubanyi GM, Harkins RN, Hermiston TW.

Mol Ther. 2007 Jul;15(7):1340-7. Epub 2007 May 1.

14.

The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p).

Shen BH, Bauzon M, Hermiston TW.

Gene Ther. 2006 Jun;13(12):986-90. Epub 2006 Mar 9.

PMID:
16525485
15.
16.
17.
18.

Effect of hypoxia on Ad5 infection, transgene expression and replication.

Shen BH, Hermiston TW.

Gene Ther. 2005 Jun;12(11):902-10.

PMID:
15690062
19.

Multigene expression from a replicating adenovirus using native viral promoters.

Bauzon M, Castro D, Karr M, Hawkins LK, Hermiston TW.

Mol Ther. 2003 Apr;7(4):526-34.

20.
21.

Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins.

Tollefson AE, Toth K, Doronin K, Kuppuswamy M, Doronina OA, Lichtenstein DL, Hermiston TW, Smith CA, Wold WS.

J Virol. 2001 Oct;75(19):8875-87.

22.
23.

Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region.

Hawkins LK, Johnson L, Bauzon M, Nye JA, Castro D, Kitzes GA, Young MD, Holt JK, Trown P, Hermiston TW.

Gene Ther. 2001 Aug;8(15):1123-31.

24.
25.

Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells.

Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, Dimitrov T, Toth K, Wells CE, Doherty PC, Wold WS.

Nature. 1998 Apr 16;392(6677):726-30.

PMID:
9565035
26.

Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes.

Dimitrov T, Krajcsi P, Hermiston TW, Tollefson AE, Hannink M, Wold WS.

J Virol. 1997 Apr;71(4):2830-7.

27.
28.
29.

The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model.

Sparer TE, Tripp RA, Dillehay DL, Hermiston TW, Wold WS, Gooding LR.

J Virol. 1996 Apr;70(4):2431-9.

30.
31.

E3 transcription unit of adenovirus.

Wold WS, Tollefson AE, Hermiston TW.

Curr Top Microbiol Immunol. 1995;199 ( Pt 1):237-74. Review. No abstract available.

PMID:
7555057
32.

Adenovirus proteins that subvert host defenses.

Wold WS, Hermiston TW, Tollefson AE.

Trends Microbiol. 1994 Nov;2(11):437-43. Review.

PMID:
7532531
33.

Sequence and functional analysis of the human adenovirus type 7 E3-gp19K protein from 17 clinical isolates.

Hermiston TW, Hellwig R, Hierholzer JC, Wold WS.

Virology. 1993 Dec;197(2):593-600.

PMID:
8249282

Supplemental Content

Loading ...
Support Center